lilotomab

Ligand id: 9950

Name: lilotomab

References
1. Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH. (2013)
Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.
Anticancer Res., 33 (1): 85-95. [PMID:23267131]
2. Stokke C, Blakkisrud J, L√łndalen A, Dahle J, Martinsen ACT, Holte H, Kolstad A. (2018)
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients.
Eur. J. Nucl. Med. Mol. Imaging, 45 (7): 1233-1241. [PMID:29470615]